Evidence map›Paper›PMID 41234857›Full record

ArticleTranslational cancer research2025

Development and verification of risk prediction nomograms for overall and specific mortality in primary small bowel cancer: a population-based study.

Yingxiang Wu, Wen Luo

Abstract read
In one paragraph

Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Yingxiang WuDepartment of General Surgery, The Central Hospital of Wuhan, Wuhan, China.
Wen LuoDepartment of General Surgery, The Central Hospital of Wuhan, Wuhan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Primary small bowel cancer (SBC) is an infrequent tumor recognized internationally, but lacks prognostic prediction models. This study aims to develop and validate prognostic nomograms for overall and specific mortality in SBC patients based on a cohort of SBC patients. Methods: Patients with SBC between 2010 and 2015 were selected from the Surveillance, Epidemiology, and End Results (SEER) database. These patients were randomized into training and verification sets at a ratio of 7:3. Univariate and multivariate analyses were performed using Cox proportional hazards and competing risk models to screen independent predictors for overall and specific mortality in these patients. Based on these predictors, nomograms were constructed to predict the risks of overall and specific mortality in SBC patients. The accuracy and reliability of the nomograms were assessed utilizing the concordance index (C-index), area under the receiver operating characteristic curve (AUC), and calibration curve. Results: This study included 6,863 patients with SBC, who were randomly split into a training set (70%, N=4,804) and a verification set (30%, N=2,059). In the training set, there were 1,630 all-cause deaths and 1,057 cancer-specific deaths, while in the verification set, 708 patients died from all causes and 431 died from cancer-specific causes. Univariate and multivariate analyses identified 12 independent predictors for overall mortality, including age, race, marital status, primary tumor location, pathological type, histological grade, tumor (T) stage, node (N) stage, metastasis (M) stage, and surgical procedure. There were also 12 independent predictors for specific mortality, encompassing age, marital status, primary tumor location, pathological type, histological grade, T stage, N stage, M stage, surgical procedure, and radiotherapy. Based on these factors, Cox proportional hazards and competing risk models were established to predict overall and specific mortality at 1, 3, and 5 years for SBC patients. The calibration curves suggested that the predicted values of the models aligned with the observed values, indicating good accuracy of the models. In the training and verification groups, the C-index values for overall survival (OS) rate were 0.789 and 0.785, respectively, and for cancer-specific mortality were 0.878 and 0.851, respectively. The AUC values for predicting OS rate at 1, 3, and 5 years were 0.827, 0.803, and 0.787 in the training set and 0.794, 0.800, and 0.807 in the verification set, respectively. These results consistently indicate that the model has good discriminatory power and predictive performance. Conclusions: This study constructed and validated risk predictive nomograms for overall and specific mortality risks in patients with primary SBC. These models are accurate and reliable and can assist clinicians in predicting survival rates in individuals with SBC.

Indexed as

Nomogramsoverall mortalityprognosissmall bowel cancer (SBC)specific mortality

Identifiers

PMID41234857
PMCPMC12605694

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.